INHIBIKASE THERAPEUTIC

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

04 12 2023 08:35:00 提供 Nasdaq GlobeNewswire

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

14 11 2023 16:30:06 提供 Nasdaq GlobeNewswire

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

07 11 2023 09:28:32 提供 Nasdaq GlobeNewswire

Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023

07 11 2023 08:00:01 提供 Nasdaq GlobeNewswire

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

16 10 2023 07:00:27 提供 Nasdaq GlobeNewswire

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

04 10 2023 08:30:00 提供 Nasdaq GlobeNewswire